1. Home
  2. ACHV vs NTHI Comparison

ACHV vs NTHI Comparison

Compare ACHV & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

HOLD

Current Price

$4.59

Market Cap

172.0M

Sector

Health Care

ML Signal

HOLD

NTHI

NeOnc Technologies Holdings Inc.

HOLD

Current Price

$5.15

Market Cap

139.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACHV
NTHI
Founded
N/A
2008
Country
United States
United States
Employees
N/A
5
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.0M
139.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ACHV
NTHI
Price
$4.59
$5.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$14.67
$15.00
AVG Volume (30 Days)
1.2M
99.5K
Earning Date
05-11-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$3.20
52 Week High
$6.15
$12.99

Technical Indicators

Market Signals
Indicator
ACHV
NTHI
Relative Strength Index (RSI) 48.02 40.64
Support Level $4.09 $4.71
Resistance Level $4.98 $5.90
Average True Range (ATR) 0.40 0.56
MACD -0.12 0.03
Stochastic Oscillator 7.56 0.00

Price Performance

Historical Comparison
ACHV
NTHI

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

Share on Social Networks: